Coherus Oncology, Inc. (CHRS)
1.07
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
1.075
0.00 (0.00%)
After-Hours: 20:00
Coherus Oncology Cash from Operations (Quarterly) : -62.09M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -62.09M |
| March 31, 2026 | -57.89M |
| December 31, 2025 | -19.72M |
| September 30, 2025 | -46.34M |
| June 30, 2025 | -46.63M |
| March 31, 2025 | -25.83M |
| December 31, 2024 | 28.61M |
| September 30, 2024 | -62.02M |
| June 30, 2024 | 59.73M |
| March 31, 2024 | -46.77M |
| December 31, 2023 | -12.94M |
| September 30, 2023 | -54.30M |
| June 30, 2023 | -38.92M |
| March 31, 2023 | -68.73M |
| December 31, 2022 | -99.95M |
| September 30, 2022 | -37.09M |
| June 30, 2022 | -50.04M |
| March 31, 2022 | -54.04M |
| December 31, 2021 | -52.32M |
| September 30, 2021 | 13.71M |
| June 30, 2021 | -0.188M |
| March 31, 2021 | 1.367M |
| December 31, 2020 | 33.12M |
| September 30, 2020 | 47.35M |
| June 30, 2020 | 60.19M |
| Date | Value |
|---|---|
| March 31, 2020 | 13.48M |
| December 31, 2019 | 17.71M |
| September 30, 2019 | 54.95M |
| June 30, 2019 | 12.68M |
| March 31, 2019 | -56.98M |
| December 31, 2018 | -47.36M |
| September 30, 2018 | -42.79M |
| June 30, 2018 | -35.53M |
| March 31, 2018 | -33.58M |
| December 31, 2017 | -29.92M |
| September 30, 2017 | -41.51M |
| June 30, 2017 | -55.57M |
| March 31, 2017 | -73.28M |
| December 31, 2016 | -86.89M |
| September 30, 2016 | -61.95M |
| June 30, 2016 | -27.39M |
| March 31, 2016 | -76.32M |
| December 31, 2015 | 5.567M |
| September 30, 2015 | -59.66M |
| June 30, 2015 | -20.84M |
| March 31, 2015 | -33.06M |
| December 31, 2014 | -33.28M |
| September 30, 2014 | -5.17M |
| June 30, 2014 | -0.217M |
| March 31, 2014 | 14.74M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -9.972M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 29.63M |
| Cash from Financing (Quarterly) | 0.144M |
| Free Cash Flow | -186.03M |
| Free Cash Flow Per Share (Quarterly) | -0.4011 |
| Free Cash Flow to Equity (Quarterly) | -61.90M |
| Free Cash Flow to Firm (Quarterly) | -59.77M |
| Free Cash Flow Yield | -131.8% |